Citations 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Guchelaar, Henk‐Jan , Schwab, Matthias , Province, Michael A. , Symmans, W. Fraser , McLeod, Howard L. , Ratain, Mark J. , Zembutsu, Hitoshi , Schaik, Ron HN van , Caudle, Kelly E. , Ingle, James N. , Symmans, W Fraser , Goetz, Matthew P. , Sangkuhl, Katrin , Whirl‐Carrillo, Michelle , Gaedigk, Andrea , Klein, Teri E. , Schwab, Matthias , Province, Mike
Clinical Pharmacology & Therapeutics | January 31, 2018 | Volume: 103 | Issue: 5 | Pages: 770-777
Tamoxifen is biotransformed by CYP2D6 to 4‐hydroxytamoxifen and 4‐hydroxy N‐desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.
A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303
Innocenti, Federico , Owzar, Kouros , Cox, Nancy, Evans, Patrick , Kubo, Michiaki , Zembutsu, Hitoshi , Jiang, Chen , Hollis, Donna, Li, Liang , Friedman, Paula N., Wang, Liewei , Glubb, Dylan M. , Hurwitz, Herbert I. , McLeod, Howard L. , Goldberg, Richard M. , Schilsky, Richard L. , Kindler, Hedy L. , Nakamura, Yusuke , Ratain, Mark J. , Cox, Nancy J. , Mushiroda, Taisei , Giacomini, Kathleen M. , Li, Liang
Clinical Cancer Research | December 6, 2011 | Volume: 18 | Issue: 2 | Pages: 577-584
Abstract Background and Aims: Cancer and Leukemia Group B 80303 was a randomized, phase III study in patients with advanced pancreatic cancer treated with gemcitabine plus either bevacizumab or placebo. We prospectively collected germline DNA and conducted a genome-wide association study (GWAS) using overall survival (OS) as the endpoint. Experimental Design: DNA from 351 patients was genotyped for more than 550,000 single-nucleotide polymorphisms (SNP). Associations between OS and SNPs were investigated using the log-linear 2-way multiplicative Cox proportional hazards model. The subset of 294 genetically European patients was used for the primary analysis. Results: A nonsynonymous SNP in interleukin (IL)17F (rs763780, H161R) and an intronic SNP in strong linkage disequilibrium (rs7771466) were associated with OS using genome-wide criteria (P ≤ 10−7). Median OS was significantly shorter (P = 2.61 × 10−8) for the rs763780 heterozygotes [3.1 months; 95% confidence interval (CI), 2.3–4.3] than for the patients without this variant (6.8 months; 95% CI, 5.8–7.3). After adjustment by stratification factors, the P value for the association was 9.51 × 10−7. Conclusions: The variant 161R form of IL-17F is a natural antagonist of the antiangiogenic effects of wild-type 161H IL-17F, and angiogenesis may play an important role in the metastatic spread of pancreatic cancer. In this preliminary study, we hypothesize that the angiogenetic potential of pancreatic cancers in patients with variant IL-17F is higher than that of tumors in patients with wild-type IL-17F, conferring worse prognosis. This exploratory GWAS may provide the foundation for testing the biology and clinical effects of novel genes and their heritable variants through mechanistic and confirmatory studies in pancreatic cancer. Clin Cancer Res; 18(2); 577–84. ©2011 AACR.